What You Need to Know About the Second Person Likely Cured of HIV

Richard Jefferys, an expert in HIV cure research, spoke to TheBodyPro about this new case of HIV remission -- and the danger in rushing to publish these stories, especially for people who live with stigma.

Featured

Depression Linked to Cognitive Dysfunction in HIV-Positive Women

More research is needed to understand the connections between HIV, mental health, and the neurocircuitry that controls executive function.

By Martha Kempner

The Next Frontier of U=U Science

Undetectable equals untransmittable (U=U) has improved HIV prevention and tackled stigma, but there are still a few questions to answer.

By Sony Salzman

CDC Explains and Defends Molecular Surveillance System

A leading researcher at the Centers for Disease Control and Prevention addressed community concerns that surveillance data will be used to put people in prison under HIV criminalization laws.

By Martha Kempner

Not Surprisingly, PopART Study Showed Community-Based Services Reduce HIV Incidence

"We don't need to spend another $140 million to find out how to retain people in care," activist David Barr writes. "We need to invest in the kinds of services people need so that they can use treatment easily and effectively."

By David Barr

People With HIV Have Substantially Higher Risk of Sudden Cardiac Death at Low CD4 Counts or Detectable Viral Load

New research involving veterans highlights the need to monitor HIV-positive patients for cardiovascular risk.

By Sony Salzman

Drug Use May Be Increasing Syphilis Rates Among HIV-Positive Cisgender Women, Studies Show

The global increase in sexually transmitted infections was a major focus of the CROI 2019 meeting in Seattle, Washington.

By Kenyon Farrow

TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects

A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.

By Martha Kempner

Viral Reservoir Can Explain Persistent Low Level Viremia With Good Adherence on ART

A CROI 2019 study suggests the dynamics of HIV proliferation in the viral reservoir might explain why viral load sometimes fails to become undetectable, especially when adherence is good.

By Simon Collins for HIV i-Base

Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies

Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.

By Simon Collins for HIV i-Base

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows

Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.

By Sony Salzman